with Regeneron putting up the lion's share (almost $120 million), while Illumina is contributing $20 million to its Series C. The cash injection will go towards the Truveta Genome Project ...
Regeneron has bought Oxular ... Oxuspheres are polymer-based drug delivery vehicles, small enough to be delivered by injection, that are designed to gradually release the active drug into the ...
Hosted on MSN11mon
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterolRegeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
Hosted on MSN1mon
Regeneron expands eye care focus with Oxular buyoutRegeneron Pharmaceuticals (NASDAQ ... The dexamethasone-based product designed as an eye injection delivered via an ocular device called Oxulumis is currently undergoing mid-stage trials.
Hagens Berman has opened an investigation into whether Regeneron may have misled investors about its marketing and reimbursement practices related to its EYLEA® product, an injection to treat ... its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback